Retrospective cohort study shows glucose-to-lymphocyte ratio predicts disease-free survival in endometrial cancer, suggesting its value as a biomarker.
GLR is an independent prognostic factor for DFS in endometrial cancer and may serve as a readily available, cost-effective biomarker. Further prospective studies are needed for validation.
No takes yet. Share an insight, caveat, or question.
Ceylan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: